Update 2020: Management of Non-Small Cell Lung Cancer

Mariam Alexander; So Yeon Kim; Haiying Cheng

doi:10.1007/s00408-020-00407-5

Update 2020: Management of Non-Small Cell Lung Cancer

Mariam Alexander, So Yeon Kim, Haiying Cheng

Oncology

Research output: Contribution to journal › Review article › peer-review

279 Scopus citations

Abstract

The past decade has seen a revolution of new advances in the management of non-small cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and treatment. The advances in systemic treatment have been driven primarily by the development of molecularly targeted therapeutics, immune checkpoint inhibitors, and anti-angiogenic agents, all of which have transformed this field with significantly improved patient outcomes. This review will address updates in lung cancer screening, liquid biopsy, and immunotherapy in the front-line setting. We discuss recent advances and highlight the plethora of new approvals of molecular-targeted therapy for subgroups of NSCLC patients with sensitizing EGFR, ALK, ROS1, RET, BRAF V600E, MET, and NTRK alterations.

Original language	English (US)
Pages (from-to)	897-907
Number of pages	11
Journal	Lung
Volume	198
Issue number	6
DOIs	https://doi.org/10.1007/s00408-020-00407-5
State	Published - Dec 2020

Keywords

Immune checkpoint inhibitors
Lung cancer
Targeted therapy

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00408-020-00407-5

Cite this

@article{b0a3afc8e241472097f558b84e60bb9c,

title = "Update 2020: Management of Non-Small Cell Lung Cancer",

abstract = "The past decade has seen a revolution of new advances in the management of non-small cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and treatment. The advances in systemic treatment have been driven primarily by the development of molecularly targeted therapeutics, immune checkpoint inhibitors, and anti-angiogenic agents, all of which have transformed this field with significantly improved patient outcomes. This review will address updates in lung cancer screening, liquid biopsy, and immunotherapy in the front-line setting. We discuss recent advances and highlight the plethora of new approvals of molecular-targeted therapy for subgroups of NSCLC patients with sensitizing EGFR, ALK, ROS1, RET, BRAF V600E, MET, and NTRK alterations.",

keywords = "Immune checkpoint inhibitors, Lung cancer, Targeted therapy",

author = "Mariam Alexander and Kim, {So Yeon} and Haiying Cheng",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2020",

month = dec,

doi = "10.1007/s00408-020-00407-5",

language = "English (US)",

volume = "198",

pages = "897--907",

journal = "Lung",

issn = "0341-2040",

publisher = "Springer New York",

number = "6",

}

TY - JOUR

T1 - Update 2020

T2 - Management of Non-Small Cell Lung Cancer

AU - Alexander, Mariam

AU - Kim, So Yeon

AU - Cheng, Haiying

PY - 2020/12

Y1 - 2020/12

N2 - The past decade has seen a revolution of new advances in the management of non-small cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and treatment. The advances in systemic treatment have been driven primarily by the development of molecularly targeted therapeutics, immune checkpoint inhibitors, and anti-angiogenic agents, all of which have transformed this field with significantly improved patient outcomes. This review will address updates in lung cancer screening, liquid biopsy, and immunotherapy in the front-line setting. We discuss recent advances and highlight the plethora of new approvals of molecular-targeted therapy for subgroups of NSCLC patients with sensitizing EGFR, ALK, ROS1, RET, BRAF V600E, MET, and NTRK alterations.

AB - The past decade has seen a revolution of new advances in the management of non-small cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and treatment. The advances in systemic treatment have been driven primarily by the development of molecularly targeted therapeutics, immune checkpoint inhibitors, and anti-angiogenic agents, all of which have transformed this field with significantly improved patient outcomes. This review will address updates in lung cancer screening, liquid biopsy, and immunotherapy in the front-line setting. We discuss recent advances and highlight the plethora of new approvals of molecular-targeted therapy for subgroups of NSCLC patients with sensitizing EGFR, ALK, ROS1, RET, BRAF V600E, MET, and NTRK alterations.

KW - Immune checkpoint inhibitors

KW - Lung cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85095985813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095985813&partnerID=8YFLogxK

U2 - 10.1007/s00408-020-00407-5

DO - 10.1007/s00408-020-00407-5

M3 - Review article

C2 - 33175991

AN - SCOPUS:85095985813

SN - 0341-2040

VL - 198

SP - 897

EP - 907

JO - Lung

JF - Lung

IS - 6

ER -

Update 2020: Management of Non-Small Cell Lung Cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this